EVELYNE ODETTE DELORME, PH.

D
(858) 558-2643
(858) 354-1572
SENIOR SCIENTIFIC INVESTIGATOR
Senior Research Scientific Investigator with extensive experience in planning an
d conducting drug discovery research using current molecular and cell biology ap
proaches. Result oriented with a strong background in identification of mechanis
m of action pathways, and their use in development of in vitro biomarkers, scree
ning and profiling assays (reporter, proliferation, apoptosis, cytotoxicity, col
ony-forming assay, protein and gene expression, western, EIA, EMSA). A common-se
nse leader who recruits and mentors highly competent research associates and fos
ters excellence in all aspects of program execution. Additional technical expert
ise includes:
* Mammalian cell culture and transfection
* Establishment of transformed stable cells
* Receptor Degradation assay
* siRNA knockdown
* Real Time PCR
* Gene cloning and site directed mutagenesis
* Peptide phage library construction and screening
* SPA, IEF
* Word, Excel, Prism, Deltagraph
* cDNA library construction and screening
* PCR arrays, Signal Transduction arrays, Phospho-protein arrays
PROFESSIONAL EXPERIENCE
CHIMEROS INC., San Diego, CA 2010
Contract Scientist,
* Established in vitro protocols for new cell lines
* Screened for novel siRNA delivery systems
ANAPHORE INC., La Jolla, CA 2009
Contract Scientist,
* Constructed, panned and screened Phage Display libraries
* Developed competition ELISA for IL23
HOLLIS-EDEN PHARMACEUTICALS, San Diego, CA 2007 - 2009
Senior Scientific Investigator, Oncology
* Led investigation to determine the Mechanism Of Action of the lead clinical st
age compound
* Identified three cellular pathways involved in the activity of the lead compou
nd while following the effect on specific biomarker, and determined the steps in
the pathways where the lead compound acted
* Wrote experimental parts of IND
LIGAND PHARMACEUTICALS, San Diego, CA
1994 - 2007
Senior Research Scientist, Molecular Oncology 2002 - 2007
* Established proof of concept for new approach to prostate cancer targeting the
androgen receptor.
* Developed degradation assay for Androgen-Independent Prostate Cancer (AIPC) id
entified as key assay for profiling small molecules.
* Initiated research on prostate cancer using PPAR gamma as a target.
* Initiated cancer research and assay development targeting the Hedgehog pathway
.
* Developed secondary assays to support medicinal chemistry's efforts for the AI
PC and the Hedgehog projects.
Senior Research Scientist, Transcription Research 1997 - 2002
Participated in the development and implementation of secondary assays used to c
haracterize thrombopoietin (TPO) receptor agonists for the Ligand/GlaxoSmithKlin
e partnership. Success in this partnership resulted in multiple milestone paymen
ts to Ligand. The drug is now in Phase III clinical trials. The drug continues t
o meet expectations. Promacta was awarded the 2009 Prix Galien USA September 30,
2009.

EVELYNE ODETTE, Ph.D. Page Two

Senior Research Scientist, Molecular Biology 1994 - 1997
* Established new reporter assays targeting inflammation. Several are still in u
se.
* Developed in vitro assays for Ligand/Abbott inflammation collaboration.
AMGEN, Inc., Thousand Oaks, CA 1986 - 1994
Research Scientist I, Inflammation Research 1992 - 1994
* Constructed random peptide phage display library producing circular peptides.
* Generated three peptide antagonists targeted against inflammation-associated c
hemokines and adhesion molecules. One peptide was produced using the peptide pha
ge display approach, the other two using a rational approach.
Research Scientist, Molecular Genetics 1991 - 1992
* Created erythropoietin (EPO) mimetics using random peptide-phage display techn
ology.
* Identified 17 candidates that were characterized with regard to biological act
ivity by the EPO project team.
Research Associate III, Molecular Genetics 1986 - 1991
* Generated second generation EPO analogs by introducing new N-Glycosylation sit
es to EPO using site-directed mutagenesis in conjunction with antibody mapping.
One of these analogs is Aranesp, Amgen's second-generation Epogen
* Created stable mammalian cell lines for each new variant.
* Analyzed physical properties of the EPO analogs using partial carbohydrate dig
estion, Western analysis, and isoelectric focusing.
* Analyzed biological activity in colony forming assays using hematopoietic prog
enitor cells from bone marrow. One analog is twice as active as the native prot
ein and is approved for use in Europe.
* Expressed and purified silk-like protein, proteinase S, PDGF, PD-ECGF, NGF and
BDNF in yeast to determine the feasibility of using yeast as a production syste
m.
POST DOCTORAL EXPERIENCE
BOSTON MEDICAL SCHOOL/VA Hospital, Biochemistry, Boston, MA 1985 - 1986
Research Biochemist (Dr. Barbara Smith)
* Characterized a new short chain collagen protein.
DANA-FARBER CANCER INSTITUTE, Molecular Cancer Genetics, Boston, MA 1983 - 1985
Post-Doctoral Fellow (Dr. Ruth Sager)
* Studied genotypic environment in which ras and myc oncogenes were tumorigenic.
Tumor formation in nude mice injected with CHO cells transfected with ras and m
yc required both Ras and Myc together.
BRANDEIS UNIVERSITY, Waltham, MA
INSTITUTE FOR PHOTOBIOLOGY OF CELLS AND ORGANELLES 1982 - 1983
Post-Doctoral Fellow (Dr. Jerome Schiff)
* Optimized protein synthesis in isolated, physiologically viable, intact pure m
itochondria from a mutant of Euglena Gracilis.
EDUCATION
Ph.D., Plant Biology Department - Cornell University, Ithaca, NY
Dissertation title: Gibberellin A20 metabolism in seedlings of G2 peas.
Advisor: Peter J. Davies
MS, Plant Biology - Cornell University
BS, Biology - New York University, New York, NY